June 19, 7am-9am | Boston, MAJoin FierceBiotech Editor-in-Chief John Carroll on Tuesday, June 19 in Boston, as he sits down with executives from GlaxoSmithKline, AstraZeneca, Sanofi, Catabasis Pharmaceuticals, and InnoThink Center to review the fast-changing ecosystem for drug R&D. Register Now! Sign up for our FREE newsletter for more news like this sent to your inbox!Both Seattle Genetics and ImmunoGen have landed plenty of pharma partnerships on the strength of their technologies, and venture investors have placed several bets on new developers of ADC. In March, for instance, biotech investor Celtic Therapeutics committed $50 million to back ADC Therapeutics, a next-generation developer of the products. "I don't think there is a major pharma or a midsized pharma with interest in cancer that doesn't have a program or isn't scrambling to put one together," Stephen Evans-Freke, a managing general partner at Celtic, told the Times.
No comments:
Post a Comment